With regards to the underlying mechanism, we identified rs6783836 in ST6GAL1 as a genome‐wide significant biomarker for HFS in patients treated with XELOX, with or without, cetuximab. This evidence concerns the gene ST6GAL1 and Hand-foot syndrome.